NEW YORK – Digital pathology company OptraScan announced Tuesday that it has closed a $30 million Series B financing round.
The round was led by molecular diagnostics firm Molbio Diagnostics.
The funding will be used to accelerate research and development and expand global sales and marketing efforts, San Jose, California-based OptraScan said in a statement. It will also be used to support initiatives to enhance artificial intelligence-based pathology algorithms and further develop digital pathology solutions. The firm "aims to enhance its portfolio of cloud-enabled digital pathology whole-slide scanning systems and AI algorithm suites designed to provide seamless, accurate diagnostics," it added.
OptraScan has developed a suite of digital pathology solutions, including slide scanning, AI-based image analysis, cloud storage, and consultation platforms. The firm received CE marking in 2022 for its OS-Ultra line of brightfield scanners and in 2018 for its whole-slide scanners.
"This investment will allow us to bring lifesaving digital pathology solutions to even more markets, helping laboratories of all sizes make timely, precise diagnoses possible," OptraScan Founder and CEO Abhi Gholap said in a statement. "Together with Molbio, we aim to bridge gaps in healthcare by delivering technology that supports high-quality, affordable diagnostics globally."